Skip to content

At least four specific psoriasis questionnaires have been developed

At least four specific psoriasis questionnaires have been developed 1

Yet others will compare diseases not affecting the skin as a comparison of disease impact. At least four specific psoriasis questionnaires have been developed. Therefore, there is a need for a psoriasis-specific instrument that better and specifically measures perceived disease severity and treatment efficacy as rated by both patients and clinicians. The questionnaire development and the validation study were independently submitted to and approved by the Toulouse University Hospital Ethics committee. Dermatologists working in hospital, private practice or both were eligible to participate in the study if managing at least two patients a month with mild to severe plaque-type psoriasis, and if prescribing local, systemic or biological treatments, or phototherapy. Prospective observational study of patients with plaque psoriasis of at least 6 months duration stratified by active and stable disease. At baseline, the mean (SD) psoriasis and area severity index (PASI) score was 17.0 (7.4) in patients with active disease and 5. The PDI questionnaire is specific to psoriasis and has been validated in a Spanish population.

At least four specific psoriasis questionnaires have been developed 2Health and Quality of Life Outcomes20064:35. Psoriasis has been linked to the depression and suicidal tendencies in the patients. Another study reported that at least 20 of psoriasis patients had contemplated suicide 10. Psoriasis specific measures are the most sensitive, however the more general measures facilitate comparisons across diseases. This study has developed the EQ-PSO questionnaire to support future psoriasis research and has informed the development of future bolt-on versions of the EQ-5D questionnaire. EQ-5D-5L questionnaire instrument plus the four psoriasis dimensions. Approximately 80 of patients affected with psoriasis have mild to moderate disease. To improve patient care, both the European and Australian consensus programme have been established to develop specific treatment goals for psoriasis.

High rates of psoriasis have been reported in people of the Faroe islands, where one study found 2. Recent work has identified that pathological worry and anxiety occur in at least a third of patients with psoriasis and that psychological interpersonal difficulties impinge on all aspects of the patient’s daily life. Where recommendations have been made for the use of drugs outside their licensed indications (‘off-label use’), these drugs are marked with a footnote in the recommendations. Before prescribing any intervention for use in children, healthcare professionals should refer to the specific SPC and the BNF for Children. Ensure the treatment strategy is developed to meet the person’s health goals so that the impact of their condition is minimised and use relevant assessment tools to ensure these goals are met. 1.3.1.16 Offer a review at least annually to adults with psoriasis who are using intermittent or short-term courses 21 of a potent or very potent corticosteroid (either as monotherapy or in combined preparations) to assess for the presence of steroid atrophy and other adverse effects. 4 developed the PASE questionnaire, which consists of symptom and function subscales. GPs in the Verona region typically refer the most severe cases and possibly those with psoriasis and joint symptoms to this particular outpatient clinic. Our results underline the importance of periodic rheumatology assessment, or at least rheumatic symptom evaluation, among psoriasis patients with tools such as EARP.

Quality Of Life In Patients With Psoriasis

At least four specific psoriasis questionnaires have been developed 34Section for Climate Therapy, Oslo University Hospital, P.O. Box 4950, Nydalen, 0424 Oslo, Norway5Department of Dermatology, Oslo University Hospital, P. Quality of life has become an important field of research. Psoriasis-specific questionnaires are explicitly developed to assess psoriasis-related QOL. To date, the use of therapies in patients with early PsA has not been reported in randomized controlled trials.

Psoriasis: Epidemiology, Clinical Features, And Quality Of Life